MEDINET Co., Ltd. will implement a business restructuring to refocus resources on cell processing operations by reviewing contract manufacturing (CDMO) of specified cell-processed products supporting cancer immunocyte therapies and regenerative medicine product development. Fixed cost reductions of 300 million yen are expected in the fiscal year ending September 2027, and approximately 600 million yen per year thereafter from the fiscal year ending September 2028. A voluntary retirement program targeting about 20 people will be conducted.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2370","jir_company_name":"MEDINET Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2370-20261030-03.pdf","jir_short_summary":"MEDINET Co., Ltd. will implement a business restructuring to refocus resources on cell processing operations by reviewing contract manufacturing (CDMO) of specified cell-processed products supporting cancer immunocyte therapies and regenerative medicine product development. Fixed cost reductions of 300 million yen are expected in the fiscal year ending September 2027, and approximately 600 million yen per year thereafter from the fiscal year ending September 2028. A voluntary retirement program targeting about 20 people will be conducted.","jir_summary":"### Key Points of the Business Restructuring\nThe Company will review resource allocation between contract manufacturing for regenerative medicine products (CDMO) and development of regenerative medicine products. By strengthening quality verification of specified cell-processed products and concentrating management resources on cell processing operations, the Company aims to improve profitability and strengthen its financial foundation to establish stable business operations. The review of regenerative medicine product businesses and prioritization of R&D will proceed to simultaneously enhance the profitability of existing businesses and improve management efficiency.\n\n### Future Impact and Personnel Adjustments\nAs part of organizational optimization, a voluntary retirement program will be implemented, targeting approximately 20 people. The retirement date is February 28, 2027, and the application period is scheduled from December 10, 2026 to December 24, 2026, with special lump-sum payments and reemployment support provided. Restructuring one-time costs are expected to be 50 million yen in the fiscal year ending September 2027, and impacts from fiscal year 2028 onward will be reflected in disclosed earnings guidance.","jir_financial_highlights":"Expected fixed cost reduction: 300 million yen (Fiscal year ending September 2027)\nExpected fixed cost reduction (thereafter): 600 million yen\/year (From fiscal year ending September 2028)","jir_category":"","jir_hashtags":"#MEDINET, #BusinessRestructuring, #CellProcessing, #RegenerativeMedicine, #CDMO","jir_key_figures":"Fixed cost reduction: 300 million yen (expected in fiscal year ending September 2027)\nFixed cost reduction: approx. 600 million yen\/year (from fiscal year ending September 2028)\nVoluntary retirement recruitment: approx. 20 people (excluding manufacturing division)","jir_meta_title":"MEDINET Co., Ltd. Implements Business Restructuring | October 2026","jir_meta_description":"MEDINET Co., Ltd. announces a business restructuring to concentrate resources on cell processing operations, implement fixed cost reduction plans, and offer a voluntary retirement program with reemployment support. This article explains the expected impacts and the company's plan to strengthen its financial base.","jir_og_title":"MEDINET Co., Ltd. Implements Business Restructuring | October 2026","jir_og_description":"Announcement of business restructuring related to regenerative medicine. Details include concentrating management resources on cell processing operations, fixed cost reductions, and implementation of a voluntary retirement program to achieve financial stabilization and growth strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":122814,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-138823","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n